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Background: The determination of sensitive chemotherapy drugs for gastric cancer (GC) is one of the greatest
challenges of adjuvant therapy. Here we evaluated the chemosensitivity of GC to anticancer drugs and the
telomerase reverse transcriptase (hTERT) mRNA expression, and investigated the relationship of them.
Methods: The GC cells which were collected from 68 patients with primary GC were primary cultured. The
chemosensitivity of GC cells to anticancer drugs was evaluated successfully using the MTT assay for 60 cases of GC
cells, and the hTERT mRNA expression was examined in 60 cases of GC tissues and corresponding normal gastric
mucosa and 6 cases of chronic superficial gastritis mucosa by in situ hybridization.
Results: Taxol, Cisplatin and 5-Fluorouracil were in general more effective than Adriamycin and Mitomycin for GC
cells, and the chemosensitivity to anticancer drugs was associated with tumor histological types and a worse tumor
grade. Compared to normal gastric mucosa tissues, hTERT mRNA expression was significantly increased in GC
(P<0.05), which was related with a worse differentiation and drug-resistance to 5-Fluorouracil or Adriamycin in GC.
Conclusions: These data demonstrate for the first time that examinations of hTERT mRNA expression as an
important factor could be used to select the chemotherapeutic drugs for GC patients.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1793217009875483
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Although the incidence of gastric cancer (GC) has been
significantly reduced in developed coutries, GC remains
one of the most common malignancies worldwide and
ranks second in terms of global cancer-related mortality
[1,2]. In recent decades, chemotherapy plays an import-
ant role in the treatment of patients with advanced GC,
although radical surgery is the only curative treatment.
Chemotherapeutic regimens for cancer patients usually
are based on the statistical results of clinical trials or the
histological type of tumor rather than the cellular sensi-
tivity to each anticancer drug [3-5]. Therefore, evalu-
ation of the effectiveness of an anticancer drug prior to* Correspondence: gm2227@sina.com
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reproduction in any medium, provided the ortreatment is critical for determining the clinical efficacy of
chemotherapy, avoiding adverse effects, and predicting
the prognosis. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) chemosensitivity test (MTT
assay) is a rapid and quantitative method to evaluate the
chemosensitivity of tumor cells to anticancer drugs [6-8].
Telomeres at the termini of each chromosome, which
consist of TTAGGG repetitive DNA sequences and vari-
ous binding proteins, have an important role in regulat-
ing the life-span of human cells and are synthesized by
telomerase as a RNA-dependent DNA polymerase
[9-11]. The core telomerase enzyme consists of two key
components, the catalytic unit telomerase reverse tran-
scriptase (hTERT) and the RNA template (hTER) [9,12].
Most of normal human somatic cells lack telomerase ac-
tivity due to the stringent transcriptional repression of
the hTERT gene. They thereby progressively lose theirtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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triggered to undergo senescence (irreversible cell growth
arrest) when their telomeres become extremely short
[13,14]. Telomerase activity or hTERT expression is
detectable in up to 90% of human cancers, in contrast to
its absence in normal tissues/cells except germ cells of
the ovary and testis [15,16]. Therefore, assessment of
hTERT expression is a useful diagnostic and prognostic
marker in many types of human malignancies, including
GC [11,17-20]. Furthermore, telomerase activity has
been reported to be related to drug resistance in several
cell lines [21,22]. Thus, hTERT expression could be used
to evaluate the efficacy of anticancer drugs.
In this study, we evaluated the chemosensitivity to
anticancer drugs and the hTERT mRNA expression in
GC, and investigated the relationship between anticancer
drug resistance and hTERT mRNA expression.
Materials and methods
Clinical data
The study included 68 patients with primary GC (mean
age 55 years; range 33–75 years; male: female, 40:28)
and was approved by the local ethics committee. The
patients underwent gastrectomy at the General Hospital
of Jinan Military Command from 2007 Jan to 2008 Dec.
After surgery, the tumor specimens and distant normal
gastric mucosa tissues were collected for this study.
None of the patients enrolled in the study had received
chemotherapy or radiotherapy prior to surgery, and
there was no evidence of any other malignancies. The
diagnoses of all GCs were histopathologically confirmed
by examination of surgical specimens. The clinical stage
of the patients and the pathologic grade of tumors were
determined according to the TNM classification and
WHO criteria, respectively. The stage was IA in 4
(5.9%), IB in 14 (20.6%), II in 23 (33.8%), IIIA in 15
(22.1%), IIIB in 6 (8.8%), IV in 6 (8.8%). There were 13
(19.1%) cases of GC with well differentiated, 20 (29.4%)
cases with moderately differentiated, 35 (51.5%) cases
with poorly differentiated. Furthermore, chronic superfi-
cial gastritis tissues (n=6) obtained from patients
which underwent gastroscopic biopsy without GC
were studied.
Anticancer drugs
The anticancer drugs tested contained Taxol (TAX)
(Taiji Co. Let., Sichuang, China), Cisplatin (CDDP) (Qilu
Co. Let., Shandong, China), 5-Fluorouracil (5-FU)
(Hualian Co. Let., Shanghai, China), Adriamycin (ADM)
(Xinhua Co. Let., Shandong, China), and Mitomycin
(MMC) (Huangshi Co. Let., Hubei, China). Each drug
was diluted in a complete medium at 10-fold therapeutic
peak plasma concentration as reported previously [8].
The complete medium consisted of RPMI 1640 (GibcoGaithersburg, MD, USA) supplemented with 10% heat-
inactivated calf serum (Gibco), 2 mM L-glutamine,
and antibiotics (100 U/ml penicillin and 100 μg/ml
streptomycin).
MTT chemosensitivity assay
The in vitro chemosensitivity of fresh surgical specimens
of GC was evaluated using the MTT assay as reported
by Mossman, with some modifications [23]. The tissue
specimens obtained during surgery were from patients
who had given written informed consent. Resected
specimens were stored in Hank’s balanced salt solution
(Gibco Gaithersburg, MD, USA) that contained 100 IU
penicillin, 100 μg streptomycin and 0.25 μg amphotericin B
(all from Gibco) per ml. Single-cell suspensions were
prepared enzymatically by incubating the specimens for
30 min in 0.5 mg/ml pronase, 0.2 mg/ml collagenase type І
and 0.2 mg/ml DNase (all from Sigma). After 2 centri-
fugations (1000 r/min), the tumor cells were suspended in
RPMI 1640 medium supplemented with 10% fetal bovine
serum, diluted to 1×105 cells/ml and 100 μl aliquots were
plated into 96 well microplates (Gibco) to give approxi-
mately 104 cells per well. The drug solutions were dissolved
in RPMI 1640 and 100 μl aliquots were added to each well
to give final concentrations of 10 μg/ml MMC, 50 μg/ml 5-
FU, 25 μg/ml CDDP, 5 μg/ml TAX, or 4 μg/ml ADM. The
control wells contained 100 μl of the cell suspension and
100 μl RPMI 1640 containing 10% FBS, and 200 μl RPMI
with 10% FBS was used as a blank. The plates were
incubated for 48 h at 37°C in a humidified atmosphere
containing 95% air and 5% CO2. 20 μl mixture of 0.4%
MTT (Sigma) and 0.1 M sodium succinate (each dissolved
in 10 μl phosphate-buffered saline and filtered through a
0.45 μm membrane filter (Millipore, Bedford, MA, USA)),
was then added and the plates were incubated for an add-
itional 3 h at 37°C. After the final incubation, 150 μl di-
methyl sulfoxide (Gibco) was added to each well to dissolve
the MTT-formazan salt and the plates were mechanically
shaken for 10 min on a mixer. The optical densities of each
well were determined using a model SM-3 easy reader
(Tianshi, Beijing, China) at 570 nm. The inhibition rates
(IR) were calculated using the formula (1 – A/B) ×100%,
where A and B represent the mean absorbance of the drug-
treated and control wells, respectively. The effects were
regarded as positive when IR values were ≥ 30%.
hTERT assay
In situ hybridization (ISH) was carried out by using
an hTERT ISH detection kit (produced by Wuhan
Boster Biological echnology Ltd.). The antisense poly-
oligonucleotide probe was digoxin-labeled. Formalin-
fixed, paraffin-embedded samples were cut at 5 μm
and adhered to poly-l-lysine treated slides. Samples
were deparaffinized and rehydrated through a graded
Table 1 Chemosensitivity of 60 cases GCs to five
anticancer drugs




TAX 6 (10%) 17 (28.3%) 37 (61.7%) 40.6% ± 9.9
CDDP 5 (8.3%) 16 (26.7%) 39 (65.0%) 38.4% ± 7.8
5-FU 5 (8.3%) 15 (25.0%) 40 (66.7%) 38.9% ± 9.2
ADM 2 (3.3%) 15 (25.0%) 43 (71.7%) 31.6% ± 8.5
MMC 1 (1.7%) 17 (28.3%) 42 (70.0%) 28.9% ± 9.8
Abbreviations: GC= gastric cancer, TAX =Taxol, CDDP=Cisplatin, 5-FU=5-
Fluorouracil, ADM= Adriamycin, MMC= Mitomycin.
Table 2 hTERT mRNA expression in 60 cases GCs
Tumor histopathologic
types
Cases hTERT mRNA expression
- + ++ +++ Positive(%)
Papillary adenocarcinoma 18 2 6 5 5 16 (88.9%)
Tubular adenocarcinoma 18 2 5 6 5 16 (88.9%)
Mucinous adenocarcinoma 12 1 3 4 4 11 (91.7%)
Signet-ring cell cancer 12 1 4 3 4 11 (91.7%)
Abbreviations: GC= gastric cancer, hTERT=human telomerase
reverse transcriptase.
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blocked using 3% hydrogen peroxide for 10 min.
The slides were digested with pepsin at 37°C for 15–
20 min. 20 μl of probe was hybridized to each slide
for 16–20 h at 40°C. After hybridization, excess
probe was removed by washing in 2×SSC at 37°C.
Tissue sections were reblocked for 20 min with
blocking reagent, and then the primary antibody
(rabbit anti-digoxin antibody) was added for 60 min
at 37°C. After washing with 0.5 M PBS three times
at 5 min each, the slides were incubated with the
secondary goat anti-rabbit immunoglobulin (IgG)
antibody conjugated with biotin for 20 min at 37°C,
then washed with 0.5 M PBS again as previously
described. Samples were next incubated with SABC
for 20 min at room temperature and rinsed with
0.5 M PBS for four times at 5 min each. The
reaction products of peroxidase were visualized by
incubation with chromogen diaminobenzidine for
15–20 min. Finally, the slides were counterstained
for nuclei by haematoxylin stain. A negative control
was prepared for each sample using a hybridization
solution without probe. The positive signals of
hTERT mRNA expression were stained with the
color of brown-yellow located in cell plasma. The
average percentage of positive cells was determined
in at least 5 areas at ×400 and assigned to one of four cat-
egories: (−)-negative or equivocal staining; (+)-weak posi-
tive, cells were stained in 1-25%; (++)-middle positive, cells
were stained in 25-50%; and (+++)-strong positive expres-
sion, cells were stained over 50%.
Statistical analysis
Quantitative results were expressed as mean ± standard
error of mean. Significant differences were determined
by Fisher’s PLSD test or a Chi-square test. The
associations analysis were tested with Spearman’s test for
nonparametric correlation. A P value of less than 0.05
was considered to be statistically significant.
Results
Chemosensitivity of gastric cancer
In the study, a total of 68 GC tissue samples (lesions)
were analyzed using the MTT assay. Sixty lesions were
considered to be evaluable (success rate: 88.2%). After
incubation with chemo-drugs for 48 h, the drug-
sensitive cells lost their adherence abilities, increased
their intracytoplasm vacuolus, and collapsed. The inhib-
ition rates of tumor cells exposed to TAX, CDDP and 5-
FU were significantly higher than those of ADM and
MMC (P<0.05) (Table 1). The inhibition rate for TAX
was equivalent to those for CDDP and 5-FU, but the
estimated efficacy for TAX was higher than those for
CDDP and 5-FU. Statistical analysis between the drugeffects and the clinicopathological features showed a
significant association between chemosensitivity to
anticancer drugs and worse histological grades. Statis-
tical differences of chemosensitivity to anticancer drugs
in different tumor histological types were also observed.
However, there were no significant differences of
chemosensitivity in different TNM stages.Expression levels of hTERT mRNA
The examination of hTERT mRNA expression was done
in GC tissues and corresponding normal gastric mucosa
of 60 patients who were obtained successful MTT assay.
In addition, 6 cases of chronic superficial gastritis mu-
cosa from patients without GC also underwent this
testing. The positive signal for hTERT mRNA expression
was a brown-yellow stain located in the cell plasma. Car-
cinomas exhibited positive hTERT significantly more fre-
quently than normal gastric mucosa tissues (P<0.05).
Signals were observed in none of the six chronic superfi-
cial gastritis samples and 60 cases of normal gastric
mucosa tissues, but in 90% (54 of 60) of the GC samples
(Table 2). Statistical analysis of the relationships between
hTERT mRNA expression and the clinicopathological
features revealed a significant association between
hTERT mRNA expression and a worse tumor differenti-
ation (P=0.013). However, there were no significant
associations between hTERT mRNA expression and the
other clinicopathological findings in GC.
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chemosensitivity
Each drug was tested to assess the relationship between
chemosensitivity to anticancer agents and hTERT
mRNA expression in GC. A close relationship was seen
between hTERT mRNA expression and 5-FU and ADM
sensitivity (P<0.05) in GC. The sensitivities of TAX,
CDDP, and MMC showed no association with the
hTERT mRNA expression in GC.Discussions
We have successfully analyzed the chemosensitivity of
GC samples to anticancer drugs using the MTT assay in
60 GC patients. Based on the overall results, GC cells
were more susceptible to CDDP and 5-FU than to ADM
and MMC, which coincided with previous reports
[24,25]. TAX is a new drug used in chemotherapy for
GC [26,27], to which GC cells were the most suscep-
tible, and should be widely used in GC. However, tumor
cells were lower susceptible to MMC than the other
drugs, suggesting that MMC alone is not effective to
treat most GCs [28]. In the present study, the response
of tumor cells to the drugs was correlated with the
histological type and grade of the tumor. Mucinous
adenocarcinoma and signet-ring cell cancer were more
sensitive to drugs than papillary adenocarcinoma and
tubular adenocarcinoma. Cells with a poor histological
grade also were more sensitive to drugs. This difference
may be because the poorly differentiated cells usually
have higher proliferative activity. It was well documented
that great variety in the response of GC cells to chemother-
apy drugs present, but the correlation between sensitivity
and clinicopathological parameters was not clear. These
data suggest that it is difficult to choose the appropriate
chemotherapies for GC based on the clinicopathological
parameters. Meanwhile, the efficacy of these drugs are less
than 45%, and adverse effects cannot be ignored. Thus,
chemosensitivity testing is essential to individualize chemo-
therapy, which could lead to the improvement in the
quality of life for GC patients.
The hTERT induction and telomerase activation are
crucial for transformed cells to stabilize their telomere
length and maintain their replicative potential, whereas
most normal human somatic cells lack telomerase activ-
ity due to the stringent repression of the hTERT gene
[13,29,30]. Therefore, telomerase activity or hTERT as-
sessment is a useful marker for diagnosis and prognosis
of various types of cancers [13]. Consistent with previ-
ous reports [31,32], our data show that hTERT mRNA
expression is higher in GC samples compared to
their corresponding normal mucosa. Moreover, hTERT
mRNA expression was associated with a worse histo-
logical grade in GC. Thus, it appears that upregulationof hTERT mRNA expression might be a predictor for
GC with a worse grade.
A previous study showed that the drug resistance that
developed against Paclitaxel, Docetaxel, Vincristine, and
Doxorubicin in MCF-7 cells was independent of the
expression of the hTERT gene and telomerase activity
[33]. So we were interested in the relationship between
hTERT mRNA upregulated expression and the drug-
resistance in GC cells. Our data showed that upregulated
hTERT mRNA expression was associated with 5-FU
(P=0.006) and ADM (P=0.028) resistance in GC cells; so
this finding suggested that hTERT mRNA expression
may be related with some anticancer drugs resistance in
GC patients, but its mechanism still need further study.
Conclusions
The determination of sensitive chemotherapy drugs for gas-
tric cancer (GC) is one of the greatest challenges of adju-
vant therapy. In our study, we found that Taxol, Cisplatin
and 5-Fluorouracil were more effective than Adriamycin
and Mitomycin for GC, and the chemosensitivity to
anticancer drugs was associated with tumor histological
types and a worse tumor grade. Compared to normal
gastric mucosa tissues, hTERT mRNA expression was sig-
nificantly increased in GC, furthermore, its increased ex-
pression was related to a worse tumor differentiation and
5-Fluorouracil or Adriamycin drug-resistance in gastric
cancer. Examinations of hTERT mRNA expression would
have reference values on selection of chemotherapeutic
drugs for gastric cancer patients.
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